Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 7NIH 1INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cyclophosphamide 109Radiotherapy 106Fluorouracil 76Doxorubicin 74Carboplatin 71Etoposide 67Cisplatin 67Vincristine 66Paclitaxel 58Chemotherapy, Adjuvant 53Leucovorin 47Specimen Handling 43Cytarabine 42Magnetic Resonance Spectroscopy 38Methotrexate 37Dexamethasone 33Taxes 31Bevacizumab 31Peripheral Blood Stem Cell Transplantation 30Gemcitabine 30Filgrastim 30Docetaxel 30Tamoxifen 28Melphalan 28Immunoglobulin G 25Epirubicin 25Disulfides 25Oxaliplatin 24Daunorubicin 24Prednisone 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × NIH × Colonoscopy × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡